Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Selpercatinib to Enhance RAI Avidity in Children, Adolescents, and Young Adults With Newly Diagnosed Differentiated Thyroid Cancers Harboring RET Fusions

NCT06458036 is registered in ClinicalTrials.gov with Children's Hospital of Philadelphia as lead sponsor.

NCT NCT06458036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06458036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Selpercatinib to Enhance RAI Avidity in Children, Adolescents, and Young Adults With Newly Diagnosed Differentiated Thyroid Cancers Harboring RET Fusions
Lead sponsor
Children's Hospital of Philadelphia
Phase
Phase 2
Overall status
Recruiting
Start date
July 29, 2024
Completion date
November 1, 2031
Enrollment
13 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, cancer, thyroid, differentiated thyroid cancer, pediatric cancer